SIBIA Neurosciences (SIBI) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SIBIA Neurosciences (SIBI)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (330)	4/22/1999 10:34:00 AM
From: scaram(o)uche	Read Replies (1) of 579

got my annual report...... I'm not used to learning anything from annual reports, but SIBI is so damn tight-lipped (a positive, IMO) and restricted in communications by pharma partners. There is a chart showing the progress of product candidates. We all know the story for the nAChR agonists 1508Y and 1553A. The new one, 3182, is indicated for Alzheimer's and ADHD, and is shown entering preclinical. So...... ADHD.... interesting! The Abeta inhibitor from Bristol-Myers Squibb..... the chart and text refer to inhibitors (plural) and the chart shows the project poised right at entry to clinical trials. Nothing new here, but, again, there's a reference to more than one molecule. For EAAR..... as we already know, the compounds from Ciba (Novartis) are named. Both compounds are shown firmly in preclinical testing, behind the BMS molecules but ahead of 3182. CGP80887 is indicated for pain and CGP79397 is indicated for epilepsy. Four additional programs are shown in discovery, including the apoptosis inhibitors and VGCC antagonists for neuropathic and chronic pain.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next